This article is from Pulmonary Circulation , volume 3 . Abstract Drug trials in neonates and children with pulmonary hypertensive vascular disease pose unique but not insurmountable challenges. Childhood is defined by growth and development. Both may influence disease and outcomes of drug trials. The developing pulmonary vascular bed and airways may be subjected to maldevelopment, maladaptation, growth arrest, or dysregulation that influence the disease phenotype. Drug therapy is influenced by... Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641736
This article is from Pulmonary Circulation , volume 2 . Abstract Pulmonary arterial hypertension (PAH) is a chronic, progressive disease of the pulmonary vasculature with a high morbidity and mortality. Its pathobiology involves at least three interacting pathways – prostacyclin (PGI2), endothelin, and nitric oxide (NO). Current treatments target these three pathways utilizing PGI2 and its analogs, endothelin receptor antagonists, and phosphodiesterase type-5 (PDE-5) inhibitors. Inhaled... Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3401867
byGrieve, Andy P.; Chow, Shien-Chung; Curram, John; Dawe, Stephen; Harnisch, Lutz O.; Henig, Noreen R.; Hung, Hsien Ming J.; Ivy, D. Dunbar; Kawut, Steven M.; Rahbar, Mohammad H.; Xiao, Shen; Wilkins, Martin R.
This article is from Pulmonary Circulation , volume 3 . Abstract In pulmonary hypertension, as in many other diseases, there is a need for a smarter approach to evaluating new treatments. The traditional randomized controlled trial has served medical science well, but constrains the development of treatments for rare diseases. A workshop was established to consider alternative clinical trial designs in pulmonary hypertension and here discusses their merits, limitations and challenges to... Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3641733
byLammers, Astrid E.; Adatia, Ian; del Cerro, Maria Jesus; Diaz, Gabriel; Freudenthal, Alexandra Heath; Freudenthal, Franz; Harikrishnan, S.; Ivy, Dunbar; Lopes, Antonio A.; Raj, J. Usha; Sandoval, Julio; Stenmark, Kurt; Haworth, Sheila G.
This article is from Pulmonary Circulation , volume 1 . Abstract The members of the Pediatric Task Force of the Pulmonary Vascular Research Institute (PVRI) were aware of the need to develop a functional classification of pulmonary hypertension in children. The proposed classification follows the same pattern and uses the same criteria as the Dana Point pulmonary hypertension specific classification for adults. Modifications were necessary for children, since age, physical growth and maturation... Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3161406
byTalati, Megha; Seeley, Erin; Ihida-Stansbury, Kaori; Delisser, Horace; McDonald, Hayes; Ye, Fei; Zhang, Xueqiong; Shyr, Yu; Caprioli, Richard; Meyrick, Barbara
This article is from Pulmonary Circulation , volume 2 . Abstract The pathogenesis of idiopathic pulmonary hypertension is poorly understood. This paper utilized histology-based Matrix-Assisted Laser Desorption Ionization Mass Spectrometry (MALDI MS) to identify as-yet unknown proteins that may be associated with the structural changes in the pulmonary arterial walls of patients with IPAH. The technology identified significant increases in two fragments of histone H1 in the IPAH cases compared... Source: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3487302